Congreso de la European Society for Dermatological Research
Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with GPP, is associated with the downregulation of biomarkers linked to innate, Th1/Th17 and neutrophilic pathways
Baum P, et al. Póster 388
SPE1167.11.2022